Elan Sweetens Deal To Counter $6.6B Takeover Bid

Law360, New York (March 4, 2013, 2:23 PM EST) -- Irish life sciences firm Elan Corp. has sweetened its offer to shareholders to remain invested in the company, offering a percentage of Elan's share of royalties from a new drug if investors vote against a $6.6 billion hostile takeover attempt by pharmaceutical investment firm Royalty Pharma LLC, Elan said Monday.

The move would unlock uncapped future royalty revenues for shareholders of Elan, which is trying to fight off a takeover bid by Royalty Pharma. Elan said it would give a percentage of its royalties from Tysabri,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.